Published in Clin Infect Dis on April 23, 2015
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (2016) 1.20
Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis (2012) 1.02
The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. Curr Opin HIV AIDS (2016) 0.98
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf (2015) 0.85
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr (2017) 0.84
Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.80
Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin? Open Forum Infect Dis (2016) 0.79
Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis. Clin Infect Dis (2015) 0.79
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV (2016) 0.78
Tenofovir and bone health. Curr Opin HIV AIDS (2016) 0.78
The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS (2016) 0.78
Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes (2015) 0.77
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infect Dis Ther (2016) 0.76
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis (2016) 0.76
Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. J Int AIDS Soc (2016) 0.76
Bone health in HIV and hepatitis B or C infections. Ther Adv Musculoskelet Dis (2016) 0.75
Bone Loss in HIV Infection. Curr Treat Options Infect Dis (2017) 0.75
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. J Gen Intern Med (2016) 0.75
Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study. AIDS (2017) 0.75
Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med (1997) 7.22
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Prevention and management of osteoporosis. World Health Organ Tech Rep Ser (2003) 2.48
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS (2008) 2.01
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials (2007) 1.97
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother (2008) 1.79
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS (2010) 1.30
Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr (2011) 1.24
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr (2009) 1.16
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One (2014) 1.12
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One (2012) 1.12
Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS (2010) 1.06
Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS (2012) 1.03
Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis (2012) 1.02
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther (2013) 1.01
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab (2013) 0.90
Low bone mineral density with tenofovir: does statistically significant mean clinically significant? Clin Infect Dis (2010) 0.88
Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. J Clin Densitom (2012) 0.86
Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl) (2011) 0.85
Prevalence of low bone mineral density in a low-income inner-city population. J Bone Miner Res (2011) 0.85
Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis (2012) 0.85
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy. J Acquir Immune Defic Syndr (2015) 0.84
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis (2014) 2.49
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis (2016) 0.76